Immune checkpoint inhibitors (ICIs), including anti-PD-1 antibodies such as pembrolizumab and nivolumab, are approved therapies for HNSCC, but anti-CTLA-4 antibodies are still under investigation and not yet considered standard of care (40, 43–47). Here, CTLA4 is linked to head and neck squamous cell carcinoma.